Marino Garcia

Mr. Garcia joined Dianthus in November of 2021 with a successful 27-year track record of building and transforming organizations in operational, strategic, commercial, and business developmental leadership roles with various small, mid-cap and large biopharmaceutical companies, including Eli Lilly, Pfizer, Aspreva (acquired by Vifor Pharma), Aptalis (acquired by Forest Labs), and Synergy. Prior to joining Dianthus, he served as Senior Vice President, Corporate and Business Development at Zealand Pharma. In this role, he sourced, negotiated, and executed various strategic transactions, including an exclusive discovery and development collaboration with Alexion Pharmaceuticals focused on peptide therapies for complement-mediated diseases. After beginning his career in large multinational biopharmaceutical companies, Marino shifted course to work with biotechnology start-ups, starting with Aspreva, a company collaborating with Roche to develop CellCept (myocophenolate mofetil) for a range of autoimmune diseases, including Lupus Nephritis, Myasthenia Gravis, and Pemphigus Vulgaris. Marino received his M.B.A from the Ivey Business School at Western University in London, Ontario and his Bachelor of Commerce from Concordia University in Montreal, Quebec.